Johnson & Johnson Gross Profit 2011-2025 | JNJ
Johnson & Johnson annual/quarterly gross profit history and growth rate from 2011 to 2025. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
- Johnson & Johnson gross profit for the quarter ending September 30, 2025 was $16.690B, a 7.62% increase year-over-year.
- Johnson & Johnson gross profit for the twelve months ending September 30, 2025 was $62.733B, a 3.6% increase year-over-year.
- Johnson & Johnson annual gross profit for 2024 was $61.35B, a 4.68% increase from 2023.
- Johnson & Johnson annual gross profit for 2023 was $58.606B, a 5.8% increase from 2022.
- Johnson & Johnson annual gross profit for 2022 was $55.394B, a 0.1% increase from 2021.
|
Johnson & Johnson Annual Gross Profit (Millions of US $) |
|
|---|---|
| 2024 | $61,350 |
| 2023 | $58,606 |
| 2022 | $55,394 |
| 2021 | $55,338 |
| 2020 | $54,157 |
| 2019 | $54,503 |
| 2018 | $54,490 |
| 2017 | $51,011 |
| 2016 | $50,101 |
| 2015 | $48,538 |
| 2014 | $51,585 |
| 2013 | $48,970 |
| 2012 | $45,566 |
| 2011 | $44,670 |
| 2010 | $42,795 |
|
Johnson & Johnson Quarterly Gross Profit (Millions of US $) |
|
|---|---|
| 2025-09-30 | $16,690 |
| 2025-06-30 | $16,115 |
| 2025-03-31 | $14,536 |
| 2024-12-31 | $15,392 |
| 2024-09-30 | $15,508 |
| 2024-06-30 | $15,578 |
| 2024-03-31 | $14,872 |
| 2023-12-31 | $14,597 |
| 2023-09-30 | $14,745 |
| 2023-06-30 | $15,057 |
| 2023-03-31 | $14,207 |
| 2022-12-31 | $9,641 |
| 2022-09-30 | $13,824 |
| 2022-06-30 | $16,101 |
| 2022-03-31 | $15,828 |
| 2021-12-31 | $8,267 |
| 2021-09-30 | $16,088 |
| 2021-06-30 | $15,725 |
| 2021-03-31 | $15,258 |
| 2020-12-31 | $14,661 |
| 2020-09-30 | $14,110 |
| 2020-06-30 | $11,757 |
| 2020-03-31 | $13,629 |
| 2019-12-31 | $13,613 |
| 2019-09-30 | $13,862 |
| 2019-06-30 | $13,622 |
| 2019-03-31 | $13,406 |
| 2018-12-31 | $13,433 |
| 2018-09-30 | $13,759 |
| 2018-06-30 | $13,903 |
| 2018-03-31 | $13,395 |
| 2017-12-31 | $12,936 |
| 2017-09-30 | $12,725 |
| 2017-06-30 | $12,993 |
| 2017-03-31 | $12,357 |
| 2016-12-31 | $12,468 |
| 2016-09-30 | $12,334 |
| 2016-06-30 | $13,146 |
| 2016-03-31 | $12,153 |
| 2015-12-31 | $12,138 |
| 2015-09-30 | $11,878 |
| 2015-06-30 | $12,430 |
| 2015-03-31 | $12,092 |
| 2014-12-31 | $12,401 |
| 2014-09-30 | $13,068 |
| 2014-06-30 | $13,456 |
| 2014-03-31 | $12,660 |
| 2013-12-31 | $12,400 |
| 2013-09-30 | $12,231 |
| 2013-06-30 | $12,388 |
| 2013-03-31 | $11,951 |
| 2012-12-31 | $11,555 |
| 2012-09-30 | $11,455 |
| 2012-06-30 | $11,332 |
| 2012-03-31 | $11,224 |
| 2011-12-31 | $10,917 |
| 2011-09-30 | $10,933 |
| 2011-06-30 | $11,425 |
| 2011-03-31 | $11,395 |
| 2010-12-31 | $10,604 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $449.502B | $88.821B |
| Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $873.884B | 42.04 |
| AbbVie (ABBV) | United States | $387.340B | 23.19 |
| Roche Holding AG (RHHBY) | Switzerland | $267.000B | 0.00 |
| Novartis AG (NVS) | Switzerland | $266.905B | 14.15 |
| Merck (MRK) | United States | $214.149B | 9.97 |
| Novo Nordisk (NVO) | Denmark | $203.961B | 11.96 |
| Pfizer (PFE) | United States | $138.902B | 7.63 |
| Sanofi (SNY) | France | $121.941B | 11.71 |
| Bayer (BAYRY) | Germany | $29.748B | 5.61 |
| Innoviva (INVA) | United States | $1.315B | 7.81 |